Most recently in 2022, a pooled analysis of 130 KIT-altered melanoma patients (AM n = 6) demonstrated an ORR of 25%, PFS of 2.7 months, and OS of 21.8 months in AM patients [115]. This evidence concerns the gene KIT and melanoma.